Shweta Maniar Sells 3,519 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST - Get Free Report) Director Shweta Maniar sold 3,519 shares of the business's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.87, for a total value of $108,631.53. Following the transaction, the director now directly owns 7,383 shares in the company, valued at $227,913.21. This trade represents a 32.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Shweta Maniar also recently made the following trade(s):

• On Tuesday, November 26th, Shweta Maniar sold 3,782 shares of RxSight stock. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16.

RxSight Trading Up 0.1 %

RxSight stock traded up $0.02 during mid-day trading on Monday, reaching $32.50. The company's stock had a trading volume of 650,967 shares, compared to its average volume of 733,917. The business has a 50 day moving average price of $37.62 and a 200-day moving average price of $45.77. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -39.16 and a beta of 1.20. RxSight, Inc. has a twelve month low of $26.29 and a twelve month high of $66.54.

RxSight (NASDAQ:RXST - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.18). The company had revenue of $35.31 million for the quarter, compared to the consensus estimate of $35.15 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. During the same quarter in the previous year, the company earned ($0.35) earnings per share. On average, equities analysts expect that RxSight, Inc. will post -0.7 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on RXST. UBS Group assumed coverage on shares of RxSight in a research note on Friday, December 6th. They issued a "buy" rating and a $52.00 target price for the company. Needham & Company LLC restated a "buy" rating and set a $66.00 target price on shares of RxSight in a research note on Monday, January 13th. Jefferies Financial Group began coverage on RxSight in a research report on Tuesday, October 29th. They set a "buy" rating and a $72.00 target price on the stock. Stifel Nicolaus reduced their price target on RxSight from $40.00 to $35.00 and set a "hold" rating for the company in a report on Monday, January 13th. Finally, Wells Fargo & Company reduced their target price on RxSight from $42.00 to $40.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $58.13.

Institutional Investors Weigh In On RxSight

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in RxSight by 17.7% in the third quarter. Geode Capital Management LLC now owns 817,117 shares of the company's stock worth $40,398,000 after purchasing an additional 122,775 shares during the period. Victory Capital Management Inc. increased its holdings in shares of RxSight by 21.0% in the third quarter. Victory Capital Management Inc. now owns 259,864 shares of the company's stock valued at $12,845,000 after buying an additional 45,161 shares in the last quarter. Algert Global LLC purchased a new stake in shares of RxSight during the second quarter valued at $2,488,000. Baillie Gifford & Co. boosted its holdings in shares of RxSight by 17.0% in the third quarter. Baillie Gifford & Co. now owns 419,004 shares of the company's stock worth $20,711,000 after buying an additional 60,789 shares during the period. Finally, Barclays PLC increased its position in shares of RxSight by 389.8% in the third quarter. Barclays PLC now owns 58,786 shares of the company's stock worth $2,906,000 after acquiring an additional 46,783 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company's stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.